Eyevensys Names Ronald Buggage as Chief Medical Officer

September 8, 2017: By Jon Swedien

eyevensysEyevensys has appointed Ronald Buggage, MD, its chief medical officer, the French company announced Sept. 4.

Eyevensys is a private clinical stage biotech company based in Paris. The company is developing its proprietary EyeCET platform, which it says is the first non-viral gene expression technology that enables safe, local, sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases.

Buggage will drive the company’s drug development strategy, overseeing clinical development programs for a broad range of ophthalmic indications based on the EyeCET platform.

Buggage was most recently division medical officer at Sanofi’s Ophthalmology Unit, Eyevensys said. He was responsible for coordination of medical and scientific activities for Sanofi’s ophthalmology portfolio, including development programs for ocular gene therapy.

He has also served as chief scientific officer at Novagali Pharma, where he was responsible for the global clinical and regulatory strategy.

Buggage has also held positions in clinical development at Novartis and Pfizer. He obtained his doctorate at the UCLA School of Medicine and specialized in ophthalmology at Emory University. He completed his training in ocular immunology and uveitis at the National Eye Institute of the National Institutes of Health.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023